The impact of serum glucose, total cholesterol and triglyceride levels on Breast Cancer risk: A retrospective study

Authors

  • Abdelhakim Ainahi Laboratoiry of Hormonology and Tumor Marker, Institut Pasteur Du Maroc http://orcid.org/0000-0001-5287-8059
  • LAHCEN WAKRIM Laboratory of Virology Unit & Immunovirology, Institut Pasteur Du Maroc
  • ABDERRAHMANE MAAROUFI Laboratoiry of Hormonology and Tumor Marker, Institut Pasteur Du Maroc
  • ABDELHAMID BARAKAT Laboratory of Human Molecular Genetics, Casablanca, Institut Pasteur Du Maroc

DOI:

https://doi.org/10.80481/revuetest40801

Keywords:

Glucose, lipid profile, hyperlidemia, breast cancer, prognosis

Abstract

Introduction:  This study aims is to explore the relationship of serum glucose, triglyceride and total cholesterol levels and breast cancer (BC).

Methods: We analyzed data in 100 women with confirmed BC and in the same number of age-matched disease-free controls. Cancer antigen 15-3 (CA15-3) and carcinoembryonic antigen (CEA) levels were estimated using chemiluminescent microparticle immunoassay technology. Glucose, triglyceride and total cholesterol levels were evaluated using dry chemistry method.

Results: In this study no significant differences were found comparing glucose and total cholesterol levels in BC cases and controls. The adjusted ORs were 0.84 (95% CI: 0.48-1.49) and 0.62 (95% CI: 0.28-1.37) respectively. However, a significant inverse association between BC risk and increasing levels of triglycerides was observed, particularly at postmenopausal stage (OR= 0.32, 95%CI: 0.14-0.77). Based on CEA and CA15-3 levels measurement and BC duration, we showed that diabetes and lipid status did not influence the course of the malignancy.

Conclusion:  Our study highlights the absence of the effect of diabetes and dyslipidemia on the risk and progression of BC. Further prospective investigations are required to confirm this important issue.

References

Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015 Mar; 136(5):359–86.

Greater Casablanca cancer registry report 2007 (French), year 2004. Available at: http://www.contrelecancer.ma/site_media/uploaded_files/Registre_des_Cancers_de_la_Re%C3%BCgion_du_grand_Casablanca_2004.pdf. Accessed 10 May 2013.

Bouchbika Z, Haddad H, Benchakroun N, Eddakaoui H, Kotbi S, Megrini A et al. Cancer incidence in Morocco: report from Casablanca registry 2005-2007. Pan Afr Med J. 2013 Sept; 16: 31.

Mechita NB, Tazi MA, Er-Raki A, Mrabet M, Saadi A, Benjaafar N et al. [Survival rate for breast cancer in Rabat (Morocco) 2005-2008]. Pan Afr Med J. 2016 Nov 11;25:144

Miki Y, Swensen J, Shattuck-Eidens D, Futreal PA, Harshman K, Tavtigian S et al. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science. 1994 Oct 7;266(5182):66-71.

Boyd NF , Cousins M, Beaton M, Kriukov V, Lockwood G, Tritchler D. Quantitative changes in dietary fat intake and serum cholesterol in women: results from a randomized, controlled trial. Am J Clin Nutr. 1990 Sep; 52(3):470-6.

Kawar LN. Barriers to breast cancer screening participation among Jordanian and Palestinian American women. Eur J Oncol Nurs. 2013 Feb; 17(1):88-94.

Mittra I. Breast cancer screening in developing countries. Prev Med. 2011 Sep; 53(3):121-2.

Smith RA, Cokkinides V, Brooks D, Saslow D, Brawley OW. Cancer screening in the United States, 2010: a review of current American Cancer Society guidelines and issues in cancer screening. CA Cancer J Clin. 2010 Mar-Apr;60(2):99-119

O’Hanlon DM, Kerin MJ, Kent P, Maher D, Grimes H, Given HF. An evaluation of preoperative CA 15-3 measurement in primary breast carcinoma. Br J Cancer. 1995 Jun; 71(6):1288-91.

Uehara M, Kinoshita T, Hojo T, Akashi-Tanaka S, Iwamoto E, Fukutomi T. Long-term prognostic study of carci¬noembryonic antigen (CEA) and carbohydrate antigen 15-3 (CA 15-3) in breast cancer. Int J Clin Oncol. 2008 Oct; 13(5):447-51.

Høyer AP, Engholm G. Serum lipids and breast cancer risk: a cohort study of 5,207 Danish women. Cancer Causes Control. 1992 Sep; 3(5):403-8.

Chang SJ, Hou MF, Tsai SM, Wu SH, Hou LA, Ma H et al. Association between lipid profiles and breast cancer among Taiwanese women. Clin Chem Lab Med. 2007; 45(9):1219-23.

Shikata K, Ninomiya T, Kiyohara Y. Diabetes mellitus and cancer risk: review of the epidemiological evidence. Cancer Sci. 2013 Jan; 104(1):9-14.

Gaard M, Tretli S, Urdal P. Risk of breast cancer in relation to blood lipids: a prospective study of 31,209 Norwegian women. Cancer Causes Control. 1994 Nov; 5(6):501-9.

Xue F, Michels KB. Diabetes, metabolic syndrome, and breast cancer: A review of the current evidence. Am J Clin Nutr. 2007 Sep; 86(3):s823-35.

Vona-Davis L, Howard-McNatt M, Rose DP. Adiposity, type 2 diabetes and the metabolic syndrome in breast cancer. Obes Rev. 2007 Sep; 8(5):395-408.

Alberti KG, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation. 2009 Oct 20; 120(16):1640-5.

Ainahi A, Barakat A, Wakrim L, Mohammadi H, ElMdaghri N, Ezzikouri S. Prostate-Specific Antigen levels in Moroccan diabetic males: A cross-sectional study. Curr Diabetes Rev. 2018;14(3):286-290.

García-Esquinas E, Guinó E, Castaño-Vinyals G, Pérez-Gómez B, Llorca J, Altzibar JM et al. Association of diabetes and diabetes treatment with incidence of breast cancer. Acta Diabetol. 2016 Feb; 53(1):99-107.

Agnoli C, Grioni S, Sieri S, Sacerdote C, Ricceri F, Tumino R et al. Metabolic syndrome and breast cancer risk: a case-cohort study nested in a multicentre Italian cohort. PLoS One. 2015 Jun 1;10(6).

Mink PJ, Shahar E, Rosamond WD, Alberg AJ, Folsom AR. Serum insulin and glucose levels and breast cancer incidence: the atherosclerosis risk in communities study. Am J Epidemiol. 2002 Aug 15;156(4):349-52.

Lambe M, Wigertz A, Garmo H, Walldius G, Jungner I, Hammar N. Impaired glucose metabolism and diabetes and the risk of breast, endometrial, and ovarian cancer. Cancer Causes Control. 2011 Aug; 22(8):1163-71.

Ryu TY, Park J, Scherer PE. Hyperglycemia as a risk factor for cancer progression.

Diabetes Metab J. 2014 Oct;38(5):330-6.

Dowling RJ, Goodwin PJ, Stambolic V. Understanding the benefit of metformin use in cancer treatment. BMC Med. 2011 Apr 6; 9:33.

Milazzo G, Giorgino F, Damante G, Sung C, Stampfer MR, Vigneri R et al. Insulin receptor expression and function in human breast cancer cell lines. Cancer Res. 1992 Jul 15;52(14):3924-30.

Sachdev D, Yee D. Disrupting insulin-like growth factor signaling as a potential cancer therapy. Mol Cancer Ther 2007; 6:1-12. Mol Cancer Ther. 2007 Jan;6(1):1-12.

Jung SY, Barrington WE, Lane DS, Chen C, Chlebowski R, Corbie-Smith G et al. Bioavailable Insulin-Like Growth Factor-I as Mediator of Racial Disparity in Obesity-Relevant Breast and Colorectal Cancer Risk among Postmenopausal Women. Menopause. Menopause. 2017 Mar;24(3):288-298.

Trinh T, Christensen SE, Brand JS, Cuzick J, Czene K, Sjölander A et al. Background risk of breast cancer influences the association between alcohol consumption and mammographic density. Br J Cancer. 2015 Jun 30; 113(1):159-65.

Brown KA, Simpson ER. Obesity and breast cancer: mechanisms and therapeutic implications. Front Biosci (Elite Ed). 2012 Jun 1; 4:2515-24.

Perks CM, Holly JM. Hormonal mechanisms underlying the relationship between obesity and breast cancer. Endocrinology and metabolism clinics of North America. 2011;40(3):485–507.

Schreier LE, Berg GA, Basilio FM, Lopez GI, Etkin AE, Wikinski RL. Lipoprotein alterations, abdominal fat distribution and breast cancer. Biochem Mol Biol Int. 1999 Apr; 47(4):681-90.

Ray G, Husain SA. Role of lipids, lipoproteins and vitamins in women with breast cancer. Clin Biochem. 2001 Feb; 34(1):71-6.

Geer EB, Shen W. Gender differences in insulin resistance, body composition, and energy balance. Gend Med. 2009; 6 Suppl 1:60-75.

La Vecchia C, Negri E, Franceschi S, Talamini R, Bruzzi P, Palli D et al. Body mass index and post-menopausal breast cancer: an age-specific analysis. Br J Cancer. 1997; 75(3):441-4.

Key TJ, Appleby PN, Reeves GK, Roddam A, Dorgan JF, Longcope C et al. Body mass index, serum sex hormones, and breast cancer risk in postmenopausal women. J Natl Cancer Inst. 2003 Aug 20; 95(16):1218-26.

Brand JS, van der Schouw YT. Testosterone, SHBG and cardiovascular health in postmenopausal women. Int J Impot Res. 2010 Mar-Apr; 22(2):91-104.

Rose DP, Haffner SM, Baillargeon J. Adiposity, the metabolic syndrome, and breast cancer in African-American and white American women. Endocr Rev. 2007 Dec;28(7):763-77.

Siemińska L, Cichoń-Lenart A, Kajdaniuk D, Kos-Kudła B, Marek B, Lenart J et al. [Sex hormones and adipocytokines in postmenopausal women]. Pol Merkur Lekarski. 2006 Jun;20(120):727-30.

Peairs KS, Barone BB, Snyder CF, Yeh HC, Stein KB, Derr RL et al. Diabetes mellitus and breast cancer outcomes: a systematic review and meta-analysis. J Clin Oncol. 2011 Jan 1;29(1):40-6

Downloads

Published

09-08-2023

Issue

Section

Articles